A Study of Evaluating the Safety and Efficacy of ATG-010 in Relapsed/Refractory Diffuse Large B-Cell Lymphoma
CompletedPhase 2Results postedLast updated 7 February 2025
What this trial tests
Phase 2 trial testing ATG-010 60 mg, orally, twice weekly, each 4 week (28-day) a cycle in Relapsed/Refractory Diffuse Large B-Cell Lymphoma (DLBCL) in 60 participants. Completed in 1 December 2023.
18 and older, any sex, with Relapsed/Refractory Diffuse Large B-Cell Lymphoma (DLBCL). Patients with the condition only — healthy volunteers not accepted.
Results — posted to ClinicalTrials.gov
Per-arm endpoint measurements with 95% confidence intervals where reported. Source: trial results section.
ORRPrimary· 12 months
ORR is defined as the proportion of patients who achieve either complete response (CR) or partial response (PR) according to the revised criteria for response assessment of lymphoma (2014 Lugano criteria: A complete metabolic response requires Score 1, 2, or 3 with or without a residual mass on 5PS(5-point scale using PET-CT). A PR requires a decrease by more than 50% in the sum of the product of the perpendicular diameters of up to six representative nodes or extranodal lesions.)
Group
Value
95% CI
ATG-010
13
PFSSecondary· 12 months
PFS is defined as the duration from start of selinexor treatment to time of central imaging laboratory determined PD (based on 2014 Lugano criteria: Progressive metabolic disease requires Score 4 or 5 with an increase in intensity of uptake from baseline. Progressive disease by CT criteria only requires an increase in the PPDs of a single node by ≥ 50%.)or death from any cause, whichever occurs first.
Group
Value
95% CI
ATG-010
1.87
1.81 – 2.10
Adverse events — posted to ClinicalTrials.gov
Time frame: From study drug dosed to 30 days after last study drug dose, up to 44 months, SAE was collected from consent, an average of 3.7 year..
Reporting threshold: 5%.
Adverse-event reports describe events observed during the trial — not all are caused by the drug.
NCT05265975 — A Study of ATG-010 in Combination With Lenalidomide and Rituximab (R2) in Adults With DLBCL and iNHL
· Phase 1, PHASE2
· terminated
NCT05354362 — A Study of ATG-010 in Combination With ATG-008 in Patients With Relapsed/Refractory Diffuse Large B-cell Lymphoma
· Phase 1
· terminated
NCT04939142 — A Study of Evaluating the Safety and Efficacy of ATG-010, Bortezomib, and Dexamethasone (SVd) Versus Bortezomib and Dexa
· Phase 3
· active not recruiting
NCT04425070 — A Study of Evaluating the Safety and Efficacy of ATG-010 Combined With Chemotherapy Sequential With ATG-010 Monotherapy
· Phase 1, PHASE2
· terminated
NCT03944057 — A Study of Evaluating the Safety and Efficacy of ATG-010 in Relapsed Refractory Multiple Myeloma
· Phase 2
· completed
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Antengene Corporation
Last refreshed: 7 February 2025
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03992339.